Effects of Trichostatin A in a Rat Model of Acute Graft-Versus-Host Disease After Liver Transplantation

Xia, Xuefeng; Liang, Chao; Líu, Hao; Hu, Qi-Da; Chen, Wei; Ma, Tao; Zhang, Yun; Bai, Xueli; Liang, Tingbo

doi:10.1097/tp.0b013e318295c04d

Cited by 7 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TSA also showed immune regulating potential in autoimmune diseases. In GVHD after bone marrow transplantation and liver allo‐transplantation, TSA enhanced the proportion and function of Tregs at doses of 2 mg/kg, 0.5 mg/kg and 0.25 mg/kg, but negatively affected the survival of recipients after liver transplantation because of the severe toxicities of TSA. Additionally, in a murine experimental allergic encephalomyelitis model, TSA (1 mg/kg, once every two days, intraperitoneal injection) attenuated the development of asthma‐like bronchial hypersensitivity in mice by decreasing the expression of Th2 cytokines and IgE production, blocking the production of inflammatory mediators in MRL/lpr mice, and decreasing Th1 cytokine production and demyelination .…”

Section: Hdac Inhibitors With Immune Suppressive Potentialmentioning

confidence: 99%

HDAC Inhibitors: Novel Immunosuppressants for Allo‐ and Xeno‐ Transplantation

et al. 2018

View full text Add to dashboard Cite

Immune rejection is the major obstacle to graft survival and quality of life of recipients after organ transplantation. The immunosuppressants applied in clinical face severe safety and efficacy issues. Histone deacetylases (HDACs) are emerging novel drug targets in the treatment of malignancies and immune disorders. HDAC inhibitors show potential as valuable immune regulators after allo-or xeno-organ transplantation. However, studies that evaluate HDAC inhibitors and mechanisms are still limited. In this review, we focused on the immunomodulatory effects of HDAC inhibitors in transplantation. Finally, we discussed the implications and challenges of applying HDAC inhibitors in allo-and xeno-transplantation.

show abstract

Section: Hdac Inhibitors With Immune Suppressive Potentialmentioning

confidence: 99%

HDAC Inhibitors: Novel Immunosuppressants for Allo‐ and Xeno‐ Transplantation

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Currently, canine models are still used to determine the effectiveness of cellular immunotherapy approaches . Also nonhuman primate models and rat models of GvHD have been characterized and used for a better understanding of the pathophysiology of acute GvHD. The advantage of mouse models is based on multiple gene deficient and transgenic animals dispensable to determine the role of individual genes or factors for GvHD.…”

Section: The Mouse Models Of Gvhd and Their Potential For Predicting mentioning

confidence: 99%

Insights into the pathogenesis of GvHD: what mice can teach us about man

Hülsdünker

Zeiser²

2014

Tissue Antigens

View full text Add to dashboard Cite

Acute graft‐vs‐host disease (GvHD) is a life‐threatening complication of allogeneic hematopoietic cell transplantation (allo‐HCT). Most of the knowledge about the biology of GvHD is derived from mouse models of this disease and therefore a critical analysis of potential advantages and disadvantages of the murine GvHD models is important to classify and understand the findings made in these models. The central events leading up to GvHD were characterized in three phases which includes the tissue damage‐phase, the T cell priming‐phase and the effector‐phase, when the disease becomes clinically overt. The role of individual cytokines, chemokines, transcription factor or receptors was studied in these models by using gene deficient or transgenic mice in the donor or recipient compartments. Besides, numerous studies have been performed in these models to prevent or treat GvHD. Several recent clinical trials were all based on previously reported findings from the mouse model of GvHD such as the trials on CCR5‐blockade, donor statin treatment, vorinostat treatment or adoptive transfer of regulatory T cells for GvHD prevention. The different mouse models for GvHD and graft‐vs‐leukemia effects are critically reviewed and their impact on current clinical practice is discussed.

show abstract

Methods for Testing Immunological Factors

Braddock

2024

Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays

View full text Add to dashboard Cite

Effects of Trichostatin A in a Rat Model of Acute Graft-Versus-Host Disease After Liver Transplantation

Abstract: TSA does not abrogate LTx-aGVHD in rats due to down-regulation of Tregs.

Cited by 7 publications

References 34 publications

HDAC Inhibitors: Novel Immunosuppressants for Allo‐ and Xeno‐ Transplantation

HDAC Inhibitors: Novel Immunosuppressants for Allo‐ and Xeno‐ Transplantation

Insights into the pathogenesis of GvHD: what mice can teach us about man

Methods for Testing Immunological Factors

Contact Info

Product

Resources

About